Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.6500
-0.0050 (-0.76%)
At close: Dec 5, 2025, 4:00 PM EST
0.6590
+0.0090 (1.38%)
After-hours: Dec 5, 2025, 7:59 PM EST
Plus Therapeutics Revenue
Plus Therapeutics had revenue of $1.40M in the quarter ending September 30, 2025, a decrease of -4.05%. This brings the company's revenue in the last twelve months to $5.26M, down -8.16% year-over-year. In the year 2024, Plus Therapeutics had annual revenue of $5.82M with 18.54% growth.
Revenue (ttm)
$5.26M
Revenue Growth
-8.16%
P/S Ratio
5.61
Revenue / Employee
$250,381
Employees
21
Market Cap
89.33M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PSTV News
- 2 days ago - Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - GlobeNewsWire
- 5 days ago - Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 12 days ago - Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire
- 16 days ago - Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - GlobeNewsWire
- 19 days ago - Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0 - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch - GlobeNewsWire